Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ReSPonD study
ISRCTN19880883Phase 2Completed
- Sponsor
- University of Bristol
- Start
- Dec 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing Exelon with Placebo (2 arms). Primary endpoints: Gait variability (step time variability) during normal walking, Gait variability (step time variability) during walking plus verbal fluency and 1 more. Started Dec 2011; status: completed.
02
Drugs
rivastigmine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on ISRCTN19880883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN19880883.